Humana increased operating profit and improved adjusted margin
Humana reported Q3 revenue of SEK 2,592m, up 4% YoY, with adjusted operating profit increasing 6% to SEK 221m. EBITDA rose to SEK 360m, and net profit reached SEK 123m. Growth was driven by price increases and efficiency improvements in Sweden, while Norway showed strong organic growth. Humana was acquired by Ambea and will delist from Nasdaq Stockholm. The company did not provide a new earnings forecast.
How this was made
The 30-second read
Why it matters
The earnings beat and margin improvement suggest operational strength, but the upcoming delisting introduces execution risk.
Market read
The earnings release provides fresh data for traders focused on Nordic health‑care stocks, while the delisting adds a short‑term risk factor.
What to watch
Potential integration challenges with Ambea and the impact of the pending delisting on liquidity.
Background
Humana reported Q3 2026 results with modest revenue growth and improved margins, followed by completion of its acquisition by Ambea and a pending delisting from Nasdaq Stockholm.
Market effects
Swedish healthcare services earnings may influence peer valuations in the Nordic health‑care sector.
Positive surprise could lift broader Stockholm exchange sentiment in the short term.
Limited; primarily a regional impact on European health‑care stocks.
Counterpoint
Despite earnings beat, the delisting and integration risk post‑acquisition could pressure the stock.
Key entities
- CompanyHumana
Swedish health‑care provider reporting Q3 2026 results.
- CompanyAmbea
Acquirer of Humana, completed the transaction.





